Mouse precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury

Chemical Research in Toxicology

Volumn 25, Issue 9, 2012, Pages 1938-1947

  Hadi, Mackenzie ^a   Chen, Yixi ^a   Starokozhko, Viktoriia ^a   Merema, Marjolijn T ^a   Groothuis, Geny M M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBAMAZEPINE; CHEMOKINE; CLOZAPINE; DICLOFENAC; GLUTATHIONE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KETOCONAZOLE; LIPOPOLYSACCHARIDE; NITRIC OXIDE; OLANZAPINE; TROGLITAZONE; VORICONAZOLE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; EX VIVO STUDY; FEMALE; IDIOSYNCRATIC DRUG INDUCED LIVER INJURY; INCUBATION TIME; INFLAMMATION; LIVER LEVEL; LIVER SLICE; LIVER TOXICITY; MOUSE; NONHUMAN; PILOT STUDY; SCREENING TEST;

ANIMALS; BENZODIAZEPINES; BIOLOGICAL MARKERS; CARBAMAZEPINE; CELL SURVIVAL; CHEMOKINES; CHROMANS; CLOZAPINE; CYTOKINES; DICLOFENAC; DRUG SYNERGISM; DRUG-INDUCED LIVER INJURY; FEMALE; GLUTATHIONE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; KETOCONAZOLE; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NITROGEN OXIDES; PYRIMIDINES; THIAZOLIDINEDIONES; TRIAZOLES;

EID: 84866395117     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx300248j     Document Type: Article

References (59)

1. Uetrecht, J. (2008) Idiosyncratic drug reactions: Past, present, and future Chem. Res. Toxicol. 21, 84-92 (Pubitemid 351219710)
2. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., and Bor, D. H. (2002) Timing of new black box warnings and withdrawals for prescription medications J. Am. Med. Assoc. 287, 2215-2220 (Pubitemid 34441937)
3. Lee, W. M. (2003) Drug-induced hepatotoxicity N. Engl. J. Med. 349, 474-485 (Pubitemid 36910027)
4. Kaplowitz, N. (2001) Drug-induced liver disorders: Implications for drug development and regulation Drug Saf. 24, 483-490 (Pubitemid 32595761)
5. Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., Crippin, J. S., Blei, A. T., Samuel, G., Reisch, J., Lee, W. M., and U.S. Acute Liver Failure Study Group (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States Ann. Intern. Med. 137, 947-954 (Pubitemid 35440240)
6. Uetrecht, J. P. (2000) Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr. Drug Metab. 1, 133-141
7. Gunawan, B. and Kaplowitz, N. (2004) Clinical perspectives on xenobiotic-induced hepatotoxicity Drug Metab. Rev. 36, 301-312 (Pubitemid 38802490)
8. Park, K., Williams, D. P., Naisbitt, D. J., Kitteringham, N. R., and Pirmohamed, M. (2005) Investigation of toxic metabolites during drug development Toxicol. Appl. Pharmacol. 207, 425-434
9. Kalgutkar, A. S., Gardner, I., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D. K., Lee, J. S., Nakai, Y., O'Donnell, J. P., Boer, J., and Harriman, S. P. (2005) A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 6, 161-225 (Pubitemid 40753853)
10. Walgren, J. L., Mitchell, M. D., and Thompson, D. C. (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity Crit. Rev. Toxicol. 35, 325-361 (Pubitemid 40691298)
11. Uetrecht, J. (2007) Idiosyncratic drug reactions: current understanding Annu. Rev. Pharmacol. Toxicol. 47, 513-539
12. Shaw, P. J., Ganey, P. E., and Roth, R. A. (2010) Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity Toxicol. Sci. 118, 7-18
13. Park, B. K., Coleman, J. W., and Kitteringham, N. R. (1987) Drug disposition and drug hypersensitivity Biochem. Pharmacol. 36, 581-590 (Pubitemid 17026072)
14. Uetrecht, J. P. (1999) New concepts in immunology relevant to idiosyncratic drug reactions: The "danger hypothesis" and innate immune system Chem. Res. Toxicol. 12, 387-395 (Pubitemid 29352401)
15. Kaplowitz, N. (2005) Idiosyncratic drug hepatotoxicity Nat. Rev. Drug Discovery 4, 489-499 (Pubitemid 40861991)
16. Roth, R. A., Luyendyk, J. P., Maddox, J. F., and Ganey, P. E. (2003) Inflammation and drug idiosyncrasy - Is there a connection? J. Pharmacol. Exp. Ther. 307, 1-8 (Pubitemid 37151885)
17. Ganey, P. E., Luyendyk, J. P., Maddox, J. F., and Roth, R. A. (2004) Adverse hepatic drug reactions: Inflammatory episodes as consequence and contributor Chem.-Biol. Interact. 150, 35-51 (Pubitemid 39441294)
18. Buchweitz, J. P., Ganey, P. E., Bursian, S. J., and Roth, R. A. (2002) Underlying endotoxemia augments toxic responses to chlorpromazine: Is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther. 300, 460-467
19. Waring, J. F., Liguori, M. J., Luyendyk, J. P., Maddox, J. F., Ganey, P. E., Stachlewitz, R. F., North, C., Blomme, E. A., and Roth, R. A. (2006) Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils J. Pharmacol. Exp. Ther. 316, 1080-1087 (Pubitemid 43345281)
20. Shaw, P. J., Hopfensperger, M. J., Ganey, P. E., and Roth, R. A. (2007) Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha Toxicol. Sci. 100, 259-266 (Pubitemid 47617822)
21. Zou, W., Beggs, K. M., Sparkenbaugh, E. M., Jones, A. D., Younis, H. S., Roth, R. A., and Ganey, P. E. (2009) Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury J. Pharmacol. Exp. Ther. 331, 114-121
22. Olinga, P., Meijer, D. K., Slooff, M. J., and Groothuis, G. M. (1997) Liver slices in in vitro pharmacotoxicology with special reference to the use of human liver tissue Toxicol. in Vitro 12, 77-100
23. Lerche-Langrand, C. and Toutain, H. J. (2000) Precision-cut liver slices: Characteristics and use for in vitro pharmaco-toxicology Toxicology 153, 221-253
24. Vickers, A. E. and Fisher, R. L. (2004) Organ slices for the evaluation of human drug toxicity Chem.-Biol. Interact. 150, 87-96 (Pubitemid 39441297)
25. Ferrero, J. L. and Brendel, K. (1997) Liver slices as a model in drug metabolism Adv. Pharmacol. 43, 131-169
26. Evdokimova, E., Taper, H., and Buc Calderon, P. (2001) Role of ATP and glycogen reserves in both paracetamol sulfation and glucuronidation by cultured precision-cut rat liver slices Toxicol. in Vitro 15, 683-690 (Pubitemid 33043957)
27. De Graaf, I. A., Van Meijeren, C. E., Pektas, F., and Koster, H. J. (2002) Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism Drug Metab. Dispos. 30, 1129-1136
28. Graaf, I. A., Groothuis, G. M., and Olinga, P. (2007) Precision-cut tissue slices as a tool to predict metabolism of novel drugs Expert Opin. Drug Metab. Toxicol. 3, 879-898 (Pubitemid 350285341)
29. van Midwoud, P. M., Janssen, J., Merema, M. T., de Graaf, I. A., Groothuis, G. M., and Verpoorte, E. (2011) On-line HPLC analysis system for metabolism and inhibition studies in precision-cut liver slices Anal. Chem. 83, 84-91
30. Elferink, M. G., Olinga, P., Draaisma, A. L., Merema, M. T., Bauerschmidt, S., Polman, J., Schoonen, W. G., and Groothuis, G. M. (2008) Microarray analysis in rat liver slices correctly predicts in vivo hepatotoxicity Toxicol. Appl. Pharmacol. 229, 300-309
31. Olinga, P., Merema, M. T., de Jager, M. H., Derks, F., Melgert, B. N., Moshage, H., Slooff, M. J., Meijer, D. K., Poelstra, K., and Groothuis, G. M. (2001) Rat liver slices as a tool to study LPS-induced inflammatory response in the liver J. Hepatol. 35, 187-194 (Pubitemid 32803473)
32. Evdokimova, E., Taper, H., and Calderon, P. B. (2002) Effects of bacterial endotoxin (lipopolysaccharides) on survival and metabolism of cultured precision-cut rat liver slices Toxicol. in Vitro 16, 47-54 (Pubitemid 34112636)
33. Elferink, M. G., Olinga, P., Draaisma, A. L., Merema, M. T., Faber, K. N., Slooff, M. J., Meijer, D. K., and Groothuis, G. M. (2004) LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process Am. J. Physiol. Gastrointest. Liver Physiol. 287, G1008-G1016 (Pubitemid 39423693)
34. de Graaf, I. A., Olinga, P., de Jager, M. H., Merema, M. T., de Kanter, R., van de Kerkhof, E. G., and Groothuis, G. M. (2010) Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies Nat. Protoc. 5, 1540-1551
35. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008) Cellular imaging predictions of clinical drug-induced liver injury Toxicol. Sci. 105, 97-105
36. Cosgrove, B. D., King, B. M., Hasan, M. A., Alexopoulos, L. G., Farazi, P. A., Hendriks, B. S., Griffith, L. G., Sorger, P. K., Tidor, B., Xu, J. J., and Lauffenburger, D. A. (2009) Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity Toxicol. Appl. Pharmacol. 237, 317-330
37. de Graaf, I. A., van der Voort, D., Brits, J. H., and Koster, H. J. (2000) Increased post-thaw viability and phase I and II biotransformation activity in cryopreserved rat liver slices after improvement of a fast-freezing method Drug Metab. Dispos. 28, 1100-1106 (Pubitemid 30662091)
38. Moshage, H., Kok, B., Huizenga, J. R., and Jansen, P. L. (1995) Nitrite and nitrate determinations in plasma: a critical evaluation Clin. Chem. 41, 892-896
39. Lee, W. M. and Senior, J. R. (2005) Recognizing drug-induced liver injury: current problems, possible solutions Toxicol. Pathol. 33, 155-164 (Pubitemid 40216814)
40. Liguori, M. J. and Waring, J. F. (2006) Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions Expert Opin. Drug Metab. Toxicol. 2, 835-846 (Pubitemid 44911535)
41. Chalasani, N. and Bjornsson, E. (2010) Risk factors for idiosyncratic drug-induced liver injury Gastroenterology 138, 2246-2259
42. Roth, R. A. and Ganey, P. E. (2011) Animal models of idiosyncratic drug-induced liver injury - Current status Crit. Rev. Toxicol. 41, 723-739
43. Yee, S. B., Ganey, P. E., and Roth, R. A. (2003) The role of Kupffer cells and TNF-alpha in monocrotaline and bacterial lipopolysaccharide-induced liver injury Toxicol. Sci. 71, 124-132 (Pubitemid 36163712)
44. Deng, X., Luyendyk, J. P., Ganey, P. E., and Roth, R. A. (2009) Inflammatory stress and idiosyncratic hepatotoxicity: Hints from animal models Pharmacol. Rev. 61, 262-282
45. Dash, A., Inman, W., Hoffmaster, K., Sevidal, S., Kelly, J., Obach, R. S., Griffith, L. G., and Tannenbaum, S. R. (2009) Liver tissue engineering in the evaluation of drug safety Expert Opin. Drug Metab. Toxicol. 5, 1159-1174
46. Roth, R. A. and Ganey, P. E. (2010) Intrinsic versus idiosyncratic drug-induced hepatotoxicity - Two villains or one? J. Pharmacol. Exp. Ther. 332, 692-697
47. Masson, M. J. and Uetrecht, J. P. (2004) Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated Chem. Res. Toxicol. 17, 82-94 (Pubitemid 38134063)
48. Amacher, D. E. (2012) The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury Expert Opin. Drug Metab. Toxicol. 8, 335-347
49. Zhang, C., Walker, L. M., Hinson, J. A., and Mayeux, P. R. (2000) Oxidant stress in rat liver after lipopolysaccharide administration: Effect of inducible nitric-oxide synthase inhibition J. Pharmacol. Exp. Ther. 293, 968-972 (Pubitemid 30417865)
50. Spolarics, Z. and Wu, J. X. (1997) Role of glutathione and catalase in H2O2 detoxification in LPS-activated hepatic endothelial and Kupffer cells Am. J. Physiol. 273, G1304-G1311
51. Roth, R. A., Harkema, J. R., Pestka, J. P., and Ganey, P. E. (1997) Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents? Toxicol. Appl. Pharmacol. 147, 300-311 (Pubitemid 28062747)
52. Ou, J., Carlos, T. M., Watkins, S. C., Saavedra, J. E., Keefer, L. K., Kim, Y. M., Harbrecht, B. G., and Billiar, T. R. (1997) Differential effects of nonselective nitric oxide synthase (NOS) and selective inducible NOS inhibition on hepatic necrosis, apoptosis, ICAM-1 expression, and neutrophil accumulation during endotoxemia Nitric Oxide 1, 404-416 (Pubitemid 28076548)
53. Li, J. and Billiar, T. R. (1999) Nitric Oxide. IV. Determinants of nitric oxide protection and toxicity in liver Am. J. Physiol. 276, G1069-73
54. Tukov, F. F., Luyendyk, J. P., Ganey, P. E., and Roth, R. A. (2007) The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury Toxicol. Sci. 100, 267-280 (Pubitemid 47617823)
55. Shaw, P. J., Ditewig, A. C., Waring, J. F., Liguori, M. J., Blomme, E. A., Ganey, P. E., and Roth, R. A. (2009) Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury Toxicol. Sci. 107, 270-280
56. Liguori, M. J., Ditewig, A. C., Maddox, J. F., Luyendyk, J. P., Lehman-McKeeman, L. D., Nelson, D. M., Bhaskaran, V. M., Waring, J. F., Ganey, P. E., Roth, R. A., and Blomme, E. A. (2010) Comparison of TNFalpha to Lipopolysaccharide as an Inflammagen to Characterize the Idiosyncratic Hepatotoxicity Potential of Drugs: Trovafloxacin as an Example Int. J. Mol. Sci. 11, 4697-4714
57. Espey, L. L. (1983) Comparison of the effect of nonsteroidal and steroidal antiinflammatory agents on prostaglandin production during ovulation in the rabbit Prostaglandins 26, 71-78 (Pubitemid 13048883)
58. Martin-Sanz, P., Mayoral, R., Casado, M., and Bosca, L. (2010) COX-2 in liver, from regeneration to hepatocarcinogenesis: What we have learned from animal models? World J. Gastroenterol. 16, 1430-1435
59. Tiegs, G. (1994) Immunotoxicology of host-response-mediated experimental liver injury J. Hepatol. 21, 890-903 (Pubitemid 24374161)